Hematopathologists encounter bone marrow biopsy specimens with marrow necrosis relatively infrequently, and the potential etiologies are diverse. Numerous causes of bone marrow necrosis have been identified, including malignancy, radiation/chemotherapy, anorexia, human immunodeficiency virus (HIV)/AIDS, medication, infection, autoimmune disease, disseminated intravascular coagulation, antiphospholipid syndrome and other thrombotic disorders, granulocyte-colony-stimulating factor (G-CSF) exposure, and hemoglobinopathies. [1] [2] [3] [4] One prior retrospective review showed the prevalence of bone marrow necrosis to be approximately 2%. 3 While bone marrow necrosis is not uncommon in site-directed biopsy specimens or autopsy material, substantial necrosis is much less common in nondirected bone marrow biopsy specimens. 3 Upon completion of this activity you will be able to:
• identify the morphologic difference between bone marrow serous fat atrophy and coagulative necrosis.
• list the potential causes of bone marrow necrosis and the most common etiologies.
• describe a reasonable work-up by special stains and/or immunohistochemistry of a bone marrow case with necrosis of unclear etiology.
specimens reviewed at our institution in that time were positive for metastatic tumor). These were non-sitedirected bone marrow biopsy specimens performed for staging or cytopenias, not directed bone biopsy specimens for suspicion of metastatic tumor. Slides from identified cases (aspirate, touch prep, clot section, and core biopsy) were reviewed by one of the authors. Cases with clusters or large areas of ghost cells and amorphous eosinophilic material were included as positive for necrosis. Percent marrow necrosis was judged as a percentage of total marrow cellularity. Clinical and laboratory information was extracted from the electronic medical record, in accordance with our section's UCSF Human Research Protection Program-approved research protocol. Statistical comparisons between two groups were performed by the Student t test with significance set as P < .05. AITL, angioimmunoblastic T-cell lymphoma; AML, acute myeloid leukemia; B-ALL, B-lymphoblastic leukemia/lymphoma; CML, chronic myelogenous leukemia; d/c, discharged; DLBCL, diffuse large B-cell lymphoma; f/u, follow-up; G-CSF, granulocyte-colony-stimulating factor; Hb, hemoglobin; HIV, human immunodeficiency virus; NA, not applicable; Nl, normal; Ph, Philadelphia chromosome; Plt, platelet; PNET, primitive neuroectodermal tumor; PTLD, posttransplant lymphoproliferative disorder; ↓, decrease; ↑, increase. a Italics signifies repeat marrow biopsy on the same patient. WBC, Hb, and Plt are reported based on UCSF hematology laboratory age-adjusted normal ranges. b For cases with bilateral bone marrow core biopsy specimens, the value of "percent necrosis" represents the percentage of marrow cellularity with necrosis from the biopsy side with disease/higher disease burden. c Cases sent to our institution for consultation where not all diagnostic slide(s) were available for retrospective review.
Results
While a large proportion of the marrow necrosis in our patient population was in the setting of chemotherapy, the typical fibrinoid necrotic changes seen in posttreatment marrows were not included in this study. Rather, the necrotic cases included showed large areas of ghost cells in a background of amorphous eosinophilic material, consistent with ischemic coagulative necrosis 4 with frequent associated osteonecrosis. Fifty-four cases of bone marrow necrosis were identified from 47 patients ❚Table 1❚. The mean (SD) age was 42 (23) years (range, 2-79 years). Seventy-two percent of these patients were male. Five patients had repeated bone marrow biopsies with a finding of necrosis, all in the setting of chemotherapy, and repeated bone marrow biopsies for treatment monitoring. According to Paydas et al 3 criteria, 46% of cases identified in our study were grade III (>50% of biopsy necrotic), 37% were grade II (20%-50% of biopsy necrotic), and 17% were grade I (<20% of biopsy necrotic).
The most common association with marrow necrosis in our patient population was hematolymphoid malignancy: 27 cases with associated ischemic necrosis were identified from 21 patients (45% of total patients with bone marrow necrosis) ❚Image 1❚, predominantly in the setting of chemotherapy. Areas of necrosis averaged 65% of cellularity (SD, 27%) in hematolymphoid cases with associated necrosis. The mean (SD) hematologic values in these patients at the time of bone marrow biopsy were as follows: WBCs, 7.7 (8.8) × 10 9 /L; hemoglobin, 10.0 (1.6) g/dL; and platelets, 94 (102) × 10 9 /L. Six (22%) cases had leukocytosis (four with circulating disease), while 13 (48%) had leukopenia. AITL, angioimmunoblastic T-cell lymphoma; AML, acute myeloid leukemia; B-ALL, B-lymphoblastic leukemia/lymphoma; CML, chronic myelogenous leukemia; d/c, discharged; DLBCL, diffuse large B-cell lymphoma; f/u, follow-up; G-CSF, granulocyte-colony-stimulating factor; Hb, hemoglobin; HIV, human immunodeficiency virus; NA, not applicable; Nl, normal; Ph, Philadelphia chromosome; Plt, platelet; PNET, primitive neuroectodermal tumor; PTLD, posttransplant lymphoproliferative disorder; ↓, decrease; ↑, increase. a Italics signifies repeat marrow biopsy on the same patient. WBC, Hb, and Plt are reported based on UCSF hematology laboratory age-adjusted normal ranges. b For cases with bilateral bone marrow core biopsy specimens, the value of "percent necrosis" represents the percentage of marrow cellularity with necrosis from the biopsy side with disease/higher disease burden. c Cases sent to our institution for consultation where not all diagnostic slide(s) were available for retrospective review.
hematolymphoid malignancy-associated marrow necrosis had recent exposure to G-CSF. Fourteen (52%) of the cases with hematolymphoid malignancy-associated marrow necrosis showed osteonecrosis as well. Osteonecrosis was not significantly associated with chemotherapy exposure (P = .48) in hematolymphoid malignancy-associated necrosis cases overall. Osteonecrosis was significantly enriched in lymphoid-lineage malignancy (P < .005). Most patients with hematolymphoid malignancy-associated marrow necrosis were deceased on follow-up (52%); of note, follow-up was somewhat limited. When date of death was known, death occurred between 2 days and 4 years after bone marrow biopsy with a finding of necrosis. For patients not known to have died, follow-up averaged 28 months (median, 26 months; range, <1-96 months).
Twenty-two cases of metastatic tumor with associated necrosis were identified from 21 unique patients (45% of total patients with bone marrow necrosis) ❚Image 2❚. Bone marrow necrosis was seen in approximately 10% of cases of metastatic tumor. Areas of necrosis averaged 30% of cellularity (SD, 18%) in metastatic tumor cases with associated necrosis, significantly less than that seen in hematolymphoid cases with associated necrosis (P < .001). The mean (SD) hematologic values in these patients at the time of bone marrow biopsy were as follows: WBCs, 7.8 (4.2) × 10 9 /L; hemoglobin, 9.8 (1.8) g/dL; and platelets, 204 (131) × 10 9 /L. Two (9%) cases had leukocytosis, while three (14%) had leukopenia. Nineteen (86%) cases had anemia, and eight © American Society for Clinical Pathology (36%) cases had thrombocytopenia. The platelet counts of the cases of metastatic tumor were significantly higher than those of the hematolymphoid malignancy cases (P < .001).
The specific metastatic malignancies with associated necrosis were the following (listed in decreasing order): prostate adenocarcinoma (five patients, 24%), Ewing sarcoma/primitive neuroectodermal tumor (PNET) (four patients, 19%), alveolar rhabdomyosarcoma (three patients, 14%), neuroblastoma (three patients, 14%), ductal breast carcinoma (two patients, 10%), and other (neuroendocrine carcinoma, urothelial carcinoma, lung adenocarcinoma, and germ cell tumor) (one patient each). As could be predicted, patients with the socalled small round blue cell tumors (Ewing sarcoma/PNET, alveolar rhabdomyosarcoma, and neuroblastoma) with associated necrosis were significantly younger than those with metastatic carcinoma with associated necrosis (16 vs 60 years, P < .001). While small round blue cell tumors are routinely staged at our institution by bone marrow biopsy, adult carcinomas are not, and a bone marrow biopsy in those cases is typically triggered only by cytopenias. Despite that difference in biopsy trigger, there were no significant differences in the percentage of marrow space occupied by tumor (67.5% vs 60%, small round blue cell vs carcinoma) or percentage of necrotic marrow cellularity (35% vs 26%, small round blue cell vs carcinoma) between these groups with associated necrosis. There was a significant difference in platelet count (263 × 10 9 /L vs 125 × 10 9 /L, small round blue cell vs carcinoma, P < .01), likely related to the younger age of patients with small round blue cell tumors and larger hematopoietic reserves. Seven (32%) of the cases with metastatic tumor-associated marrow necrosis had recent preceding chemotherapy exposure. Ten (45%) of the cases with metastatic tumor-associated marrow necrosis showed osteonecrosis as well, with significant areas of bone without osteocytes and/ or with bony degradation. Osteonecrosis was present in every case of metastatic prostate adenocarcinoma with associated A B C ❚Image 1❚ Representative morphologic findings in a bone marrow biopsy specimen with necrosis due to diffuse large B-cell lymphoma. Wright-Giemsa-stained cytologic preparation (A, ×1,000) shows lymphoma cells and tingible body macrophages. The H&E-stained core biopsy specimen (B, C) reveals diffuse sheets of lymphoma and coagulative necrosis (B, ×100; C, ×1,000). marrow necrosis; compared with the overall metastatic tumor with necrosis cohort, the presence of osteonecrosis significantly enriched for prostatic adenocarcinoma (P < .005). All cases with metastasis-associated marrow necrosis had viable disease by morphology. Most patients with metastatic tumorassociated marrow necrosis were deceased on follow-up (62%); of note, follow-up was somewhat limited. Patients with small round blue cell tumors were significantly less likely to be deceased on follow-up (P < .05), likely related to the younger age of patients with small round blue cell tumors and fewer comorbidities compared with older adults with other metastatic tumors. When date of death was known, death occurred between 6 days and 2 years after bone marrow biopsy with a finding of necrosis. For patients not known to have died, follow-up averaged 14 months (median, 5 months; range, 0-72 months). One case of bone marrow necrosis with associated microorganisms was identified: a 51-year-old man with AML with myelodysplasia-related changes following multiple rounds of induction chemotherapy who had neutropenic fevers while in morphologic remission. Serum b-d-glucan (marker of invasive fungal infection) was above the quantifiable range (>500 pg/mL; normal range, <60 pg/mL). Serum galactomannan Aspergillus antigen was normal. Multiple cultures had been negative for bacteria, mycobacteria, and fungi. The patient had been broadly covered with antimicrobials. Bone marrow 1.5 weeks after the b-d-glucan level was drawn showed disease remission with no increase in blasts. Large yeast forms with narrow-based budding were seen on the clot section with associated cellular necrosis; elongate Grocott's methenamine silver (GMS)-positive forms potentially consistent with pseudohyphae were noted ❚Image 3❚. No yeast forms or necrosis were seen on the core biopsy specimen. Unfortunately, bone marrow biopsy material was not sent for culture. Morphologic differential diagnosis included Cryptococcus species and Candida species, among others. Serum Cryptococcus, Coccidioides, and Histoplasma capsulatum antigens were negative. Clot tissue was submitted for polymerase chain reaction (PCR)-based fungal DNA detection and speciation using both fungal ribosome 28S and internal transcribed spacer sequence (ITS) DNA as targets. Candida albicans DNA was detected with the ITS primer set. Five patients had bone marrow necrosis without evidence of malignancy (10% of patients with necrosis) ❚Image 4❚. Bone marrow necrosis averaged 58% of cellularity (SD, 24%) in bone marrow necrosis without evidence of malignancy. The mean (SD) hematologic values in these five patients at the time of bone marrow biopsy were as follows: WBCs, 3.6 (1.8) × 10 9 /L; hemoglobin, 9.7 (1.3) g/dL; and platelets, 79 (49) × 10 9 /L. Two cases had leukopenia, and none showed leukocytosis. All five cases had anemia.
Four cases had thrombocytopenia, while none had thrombocytosis. The WBC count and platelet count of the nonmalignant cases were significantly lower than those in the cases of metastatic tumor (P < .05). There were no statistically significant differences between the average hematologic values in the patients with hematolymphoid disease-associated marrow necrosis vs benign marrow necrosis; however, no cases of leukocytosis were seen in the benign necrosis cases. Three of the five patients presented with cytopenias and were found to have marrow necrosis without evidence of hematolymphoid malignancy and no identifiable cause of necrosis. Two of the three idiopathic cases had no specific diagnosis; the third now carries an outside diagnosis of myelodysplastic syndrome with normal karyotype and no increase in blasts 4 years later. The fourth of the five patients had a history of antiphospholipid syndrome and was discharged home 1 month after marrow biopsy. The final patient with benign marrow necrosis had a history of HIV and hemoglobin SC disease, had fevers, and was found to have marrow necrosis. He was alive at a 4-month follow-up. One case showed nonnecrotizing granulomas, but no morphologically identifiable microorganisms were seen in these cases of marrow necrosis without associated malignancy. Marrow cultures were performed on only one sample (from the patient with HIV and hemoglobin SC disease) and were negative for acid-fast bacilli (AFB) and fungus. No patients with bone marrow necrosis without associated malignancy were deceased on limited followup. None of the patients with benign marrow necrosis had reported recent exposure to G-CSF.
Discussion
In a 10-year retrospective analysis at our academic medical center, approximately 0.3% of our non-site-directed bone marrow cases showed significant necrosis. Most were secondary to metastatic tumor or hematolymphoid malignancy (together, 90% of necrosis cases). In the cases of malignancy-associated necrosis, we presume that the necrotic cells represent necrotic malignant cells and not necrotic trilineage hematopoiesis. This was morphologically apparent in the cases of metastatic tumor due to the generally abundant viable tumor cells and variably retained architectural patterns in the necrotic cells. In the cases of © American Society for Clinical Pathology hematolymphoid malignancy, the identity of the necrotic cells was definitively confirmed in four cases by immunohistochemical stains, which showed specific dense, diffuse staining of necrotic cells. In addition, the presence of necrotic cells with adjacent viable neoplastic hematolymphoid cells in 15 cases (56% of the hematolymphoid malignancy-associated necrosis cases) is correlative evidence that necrotic cells were malignant cells.
Patients with malignancy-associated marrow necrosis generally had a poor prognosis (approximately 55% mortality on follow-up regardless of tumor type), although this could be related to the poor prognosis of their underlying malignancies. Remarkably, some surviving patients with malignancy-associated marrow necrosis have achieved durable remissions (up to 8 years) with return of normal blood counts.
Metastatic tumor-associated marrow necrosis was repeatedly seen in metastatic prostate adenocarcinoma, Ewing sarcoma/PNET, alveolar rhabdomyosarcoma, neuroblastoma, and ductal breast carcinoma. Relative to our incidence of each type of metastatic tumor in bone marrow, necrosis tended to enrich in prostate adenocarcinoma (42% of total metastatic prostatic adenocarcinoma), Ewing/PNET (40% of total metastatic Ewing/PNET), and neuroendocrine carcinoma (33% of total metastatic neuroendocrine carcinoma) (data not shown). Neuroblastoma cases showed the least necrosis, present in only 5% of total metastatic neuroblastoma marrow cases (data not shown). Metastatic prostatic adenocarcinoma was uniformly associated with osteonecrosis despite having relatively low necrotic burden (5%-30% of marrow cellularity necrotic), potentially reflecting an effect of prostatic acid phosphatase and/or the osteolytic/osteopenic bone lesions found in radiologically osteoblastic prostate adenocarcinoma metastases. 5, 6 In hematolymphoid malignancy-associated marrow necrosis, cases of lymphoid malignancy predominated over cases of myeloid malignancy in our study. This is in contrast to our general patient mix for bone marrow biopsies at our academic hematopathology service, which are predominantly for evaluation of myeloid malignancy. Lymphoid cases were enriched for high-grade disease (lymphoblastic, DLBCL/high-grade B-cell lymphoma, or BL), as could be predicted and as mentioned by Sovani et al. 7 While B-lymphoblastic leukemia/lymphoma has been reported to be the most common malignant cause of marrow necrosis, 4 equal numbers of patients in the present study had DLBCL/high-grade B-cell lymphoma (five cases each) compared with B-lymphoblastic leukemia/ lymphoma (five cases). Lymphoid disease was statistically associated with osteonecrosis, potentially reflecting a global marrow ischemic state induced by highly proliferative malignant lymphoid cells. Alternately, it has been suggested that the expansive growth of tumor cells within the noncompliant space of the bone marrow cavity impedes blood flow, causing ischemic necrosis. 8 AML cases with necrosis were enriched for those with monocytic features. This is in contrast to the fact that AMLs with monocytic differentiation are a minority of AML cases overall: total monocytic/monoblastic cases represented only 13% of overall AMLs in one German prospective study. 9 None of the three monocytic AML cases showed associated osteonecrosis. This potentially suggests a particular sensitivity to necrosis for monocytic blasts that does not extend to adjacent bony trabeculae.
In contrast to the previously reported cases of nonneoplastic marrow necrosis, 3, 4 we identified only one case with an infectious etiology (C albicans) other than HIV. This likely represents our patient mix, and we suggest that bone marrow necrosis seen in US tertiary care centers is unlikely to be related to infectious etiologies, although an infectious source should always be investigated (by marrow culture and histologic special stains). In addition, more modern approaches for identifying unculturable microorganisms (or microorganisms in which material was not sent for culture) such as PCR of tissue-extracted DNA for pan-genera fungal detection or next-generation sequencing could be considered. 10 We did identify bone marrow necrosis cases with associated antiphospholipid syndrome and hemoglobinopathy, as has been previously reported. 1, 4 In those cases with necrosis without identifiable malignancy, the prognosis was much better, with no deaths (although our follow-up is incomplete).
To our knowledge, this study represents the largest cohort of antemortem bone marrow necrosis in nondirected biopsy specimens in recent literature. A larger number of cases were identified in the 1979 report from Norgard et al, 11 although that report appears to have had looser morphologic inclusion criteria and did not require the presence of definitively necrotic ghost cells. We undertook this study because a reexamination of the clinicopathologic correlates of marrow necrosis is needed, given the marked recent changes in hematolymphoid malignancy diagnostic criteria and changes in treatment modalities for hematolymphoid malignancies. In addition, this study includes pediatric cases, routine review of aspirate smears, and several patients with a repeat finding of bone marrow necrosis; these study expansions, compared with that of Paydas et al, 3 will allow better applicability to practicing hematopathologists reviewing cases with a finding of bone marrow necrosis.
We confirm the reported predominance of marrow malignancy as the cause of necrosis. The increased incidence of necrosis associated with DLBCL/high-grade B-cell lymphoma has not been identified 4 and could be due to more aggressive modern therapies, including immunotherapy. In those cases with necrosis without identifiable malignancy, the etiology of necrosis was unclear in 60% of the cases and attributed to antiphospholipid syndrome and concurrent hemoglobinopathy and HIV in one case each.
In bone marrow biopsy specimens containing necrosis without morphologically identifiable malignancy or a clinical history of metastatic/hematolymphoid malignancy, a broad differential diagnosis should be considered ❚Table 2❚. 3, 4, 7, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] It should be highlighted that in our series, all cases with metastasis-associated marrow necrosis had viable disease identifiable by morphology. Every bone marrow case with necrosis requires morphologic evaluation with examination of the pattern of cellular necrosis, presence of nonnecrotic tumor cells or hematolymphoid neoplasm, granulomas, infectious etiologies, and other specific morphologic features. If, despite careful morphologic evaluation, no specific etiology of marrow necrosis can be identified, an initial panel of stains could be considered to evaluate for infectious etiologies and broad categories of neoplasms associated with necrosis in the bone marrow: GMS, AFB, CD3, CD20, CD34, CD117, and pan-cytokeratin (ie, AE1/ AE3 + CAM 5.2). This panel may highlight micro-organisms or hematolymphoid neoplasm or metastatic tumor that could not be appreciated morphologically. This possible stain panel does not cover every etiology of metastatic tumor associated with bone marrow necrosis (ie, rare etiologies such as melanoma or Kaposi sarcoma) but rather covers the most frequent etiologies (and those identified in this report). In addition, if a repeat bone marrow biopsy is performed, marrow culture and/or flow cytometry could be considered. 
